In a nationwide study of myasthenia gravis in Sweden, nearly half of patients (47%) reported an unsatisfactory symptom state per Myasthenia Gravis-Activities of Daily Living (MG-ADL) score ≥3 points. Improved treatments are required.
Why this matters
Myasthenia gravis (MG) is a chronic neuroinflammatory condition that causes fluctuating skeletal muscle weakness and fatiguability, with a significant impact on quality of life.
The MG-ADL is an MG-specific patient-reported outcome that measures disease activity over time. MG-ADL has good correlation with quantitative MG measures, such as the quantitative MG score (QMG), the MG composite (MGC), and the MG 15-item Quality of Life Scale (MG-QOL15).
The Genes and Environment in MG (GMEG) study is a nationwide Swedish cohort to provide insights into the etiology and clinical features of MG. MG-ADL scores were investigated in the cohort to gain a picture of patient-reported MG disease severity in Sweden.